- Home
- FUSB vs XGN Comparison
FUSB vs XGN Comparison
Compare FUSB & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSB
- XGN
- Stock Information
- Founded
- FUSB 1952
- XGN 2002
- Country
- FUSB United States
- XGN United States
- Employees
- FUSB N/A
- XGN N/A
- Industry
- FUSB Major Banks
- XGN Medical Specialities
- Sector
- FUSB Finance
- XGN Health Care
- Exchange
- FUSB Nasdaq
- XGN Nasdaq
- Market Cap
- FUSB 73.3M
- XGN 72.3M
- IPO Year
- FUSB N/A
- XGN 2019
- Fundamental
- Price
- FUSB $12.99
- XGN $4.01
- Analyst Decision
- FUSB
- XGN Strong Buy
- Analyst Count
- FUSB 0
- XGN 2
- Target Price
- FUSB N/A
- XGN $7.50
- AVG Volume (30 Days)
- FUSB 2.0K
- XGN 197.2K
- Earning Date
- FUSB 01-31-2025
- XGN 11-12-2024
- Dividend Yield
- FUSB 1.74%
- XGN N/A
- EPS Growth
- FUSB 5.90
- XGN N/A
- EPS
- FUSB 1.40
- XGN N/A
- Revenue
- FUSB $40,310,000.00
- XGN $55,751,000.00
- Revenue This Year
- FUSB N/A
- XGN $6.81
- Revenue Next Year
- FUSB N/A
- XGN $17.72
- P/E Ratio
- FUSB $8.81
- XGN N/A
- Revenue Growth
- FUSB 0.79
- XGN 8.00
- 52 Week Low
- FUSB $8.66
- XGN $1.30
- 52 Week High
- FUSB $14.30
- XGN $6.22
- Technical
- Relative Strength Index (RSI)
- FUSB 50.96
- XGN 52.22
- Support Level
- FUSB $12.34
- XGN $2.76
- Resistance Level
- FUSB $13.00
- XGN $3.42
- Average True Range (ATR)
- FUSB 0.48
- XGN 0.53
- MACD
- FUSB -0.01
- XGN -0.01
- Stochastic Oscillator
- FUSB 87.27
- XGN 56.10
About FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals and other individuals.
About XGN Exagen Inc.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.